Transcriptomics

Dataset Information

0

NCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules


ABSTRACT: This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA content and integrity. Pre-treatment gene expressions impacted clinical response, including several near 17q12, which with ERBB2, may better identify chemoresponsiveness.

ORGANISM(S): Homo sapiens

PROVIDER: GSE66999 | GEO | 2015/11/11

SECONDARY ACCESSION(S): PRJNA278663

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2015-11-11 | E-GEOD-66999 | biostudies-arrayexpress
| S-EPMC4627986 | biostudies-literature
| S-EPMC4565534 | biostudies-literature
2020-12-25 | GSE152802 | GEO
| S-EPMC4559832 | biostudies-literature
| S-EPMC4700696 | biostudies-literature
| S-EPMC5363272 | biostudies-literature
| S-EPMC3612593 | biostudies-literature
| S-EPMC4681581 | biostudies-literature
| S-EPMC4289722 | biostudies-literature